Advancing a Novel Immunostimulatory  Agent to Fight Cancer

​Cancer is a major public health issue resulting in 10 million deaths world-wide annually.

We can do better.​

Future improvements in cancer treatment depend on our ability

to move beyond the conventional and engage the immune system to produce better patient outcomes.

Our Technology
 

Our lead candidate, MIE-101, is derived from a plant virus that is not infectious to mammals. MIE-101 is designed to stimulate the immune system to recognize and fight cancer. 

Immuno-Oncology - Humans

 

MIE-101 is based on the plant virus cowpea mosaic virus (CPMV) which is infectious to certain plants but not to animals including mice, dogs and humans.  CPMV does however resemble features of mammalian viruses, including its outer protein structure and its genetic nucleic acid, both components of which are recognized by the innate immune system through pattern recognition receptors (PRRs) .  The plant viral nanoparticle is directly administered into the tumor to activate the immune system within and elicit local and system anti-tumor immunity.

Immuno-Oncology - Companion Animals

Mosaic IE's lead veterinary compound MIE-201, is based on exactly the same concept as its lead human oncology product candidate and has demonstrated promising antitumor effects as a monotherapy and in combination with standard of care such as chemotherapy and radiation in dogs with spontaneous solid tumors. 

New studies are planned to help inform development of the platform in human cancer patients while also exploring the potential in companion animals.To learn more about our companion animal treatment platform and plans, please visit the Mosaic ImmunoEngineering Animal Health website.

2plant and holo.jpg

Contact Us

For any inquiries, please email us at
info@mosaicie.com